Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis

SummaryBackground e number of trials have assessed various chemotherapy regimens for the treatment of advanced cervical cancer, but there is uncertainty about the magnitude of survival benefits. s rched (last update January 2006) for trials in women with locally advanced or disseminated cervical cancer that compared neo-adjuvant or concurrent chemotherapy plus radiotherapy versus radiotherapy alone; or different chemotherapy regimens among themselves (with or without background radiotherapy in both arms). Sixty-five trials were identified with survival data on 11,180 women. Results for survival were combined with fixed and random effects models and between-study heterogeneity was estimated. Separate results were obtained for different regimens, cycle length, and type of chemotherapy (neo-adjuvant, concurrent, without radiotherapy). s two comparisons had survival data on 3837 women randomized to receive chemotherapy plus radiotherapy versus radiotherapy alone; the summary relative hazard for mortality was 0.95, 95% CI, 0.83–1.08. Modest between-study heterogeneity (I2 = 38%) seemed to be due to contradictory results in early trials; trials published in the last decade had a summary relative hazard 0.89 (95% CI, 0.78–1.02) and no between-study heterogeneity (I2 = 0%). Results were similar for neo-adjuvant chemotherapy and for concurrent chemo-radiotherapy. Cisplatin or cisplatin-based combinations had no significant benefit overall, but a potential benefit was seen with short-length cycles (⩽14 days) and a marginally significant harm with longer-length cycles (summary relative hazards 0.80, 95% CI, 0.66–0.99 and 1.18, 95% CI, 1.02–1.38, respectively). The summary relative hazard was 1.02, (95% CI, 0.84–1.24) for trials using neo-adjuvant chemotherapy and 0.85 (95% CI, 0.73–1.00) for trials using concurrent chemotherapy. sions ce on chemotherapy in women with advanced cervical cancer is not encouraging for major survival benefits. However, small benefits have been observed in some trials, especially with short-length cycles of cisplatin-based regimens and concurrent chemotherapy and radiotherapy.